{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T14:56:43Z","timestamp":1768661803917,"version":"3.49.0"},"reference-count":45,"publisher":"Pharmaceutical Society of Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,1,16]]},"DOI":"10.1248\/bpb.b25-00620","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:09:24Z","timestamp":1768514964000},"page":"113-121","source":"Crossref","is-referenced-by-count":0,"title":["Drug-Induced Liver Injury with Eosinophilia: A Case\u2013Control Study Using Electronic Medical Records"],"prefix":"10.1248","volume":"49","author":[{"given":"Kimino","family":"Minagawa","sequence":"first","affiliation":[{"name":"Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center, Nihon University School of Medicine, 30\u20131 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173\u20138610, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Akimoto","sequence":"additional","affiliation":[{"name":"Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center, Nihon University School of Medicine, 30\u20131 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173\u20138610, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Department of Biomedical Sciences, Nihon University School of Medicine, 30\u20131 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173\u20138610, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Nagashima","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Department of Biomedical Sciences, Nihon University School of Medicine, 30\u20131 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173\u20138610, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center, Nihon University School of Medicine, 30\u20131 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173\u20138610, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Asai","sequence":"additional","affiliation":[{"name":"Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center, Nihon University School of Medicine, 30\u20131 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173\u20138610, Japan"},{"name":"Division of Pharmacology, Department of Biomedical Sciences, Nihon University School of Medicine, 30\u20131 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173\u20138610, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bj\u00f6rnsson HK, Bj\u00f6rnsson ES. Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management. <i>Eur. J. Intern. Med.<\/i>, <b>97<\/b>, 26\u201331 (2022).","DOI":"10.1016\/j.ejim.2021.10.035"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hoofnagle JH, Bj\u00f6rnsson ES. Drug-induced liver injury\u2014types and phenotypes. <i>N. Engl. J. Med.<\/i>, <b>381<\/b>, 264\u2013273 (2019).","DOI":"10.1056\/NEJMra1816149"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Babai S, Auclert L, Le-Lou\u00ebt H. Safety data and withdrawal of hepatotoxic drugs. <i>Therapie<\/i>, <b>76<\/b>, 715\u2013723 (2021).","DOI":"10.1016\/j.therap.2018.02.004"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Saleh AK, El-Masry TA, El-Kadem AH, Ashour NA, El-Mahdy NA. Exploring drug-induced liver injury: comprehensive insights into mechanisms and management of hepatotoxic agents. <i>Future J. Pharm. Sci.<\/i>, <b>11<\/b>, 38 (2025).","DOI":"10.1186\/s43094-025-00788-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Uetrecht J. Mechanistic studies of idiosyncratic DILI: clinical implications. <i>Front. Pharmacol.<\/i>, <b>10<\/b>, 837 (2019).","DOI":"10.3389\/fphar.2019.00837"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Teschke R, Uetrecht J. Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues. <i>Ann. Transl. Med.<\/i>, <b>9<\/b>, 730 (2021).","DOI":"10.21037\/atm-2020-ubih-05"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP. Drug-induced liver injury: recent advances in diagnosis and risk assessment. <i>Gut<\/i>, <b>66<\/b>, 1154\u20131164 (2017).","DOI":"10.1136\/gutjnl-2016-313369"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites. <i>J. Allergy Clin. Immunol.<\/i>, <b>113<\/b>, 30\u201337 (2004).","DOI":"10.1016\/j.jaci.2003.10.050"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Gleich GJ. Mechanisms of eosinophil-associated inflammation. <i>J. Allergy Clin. Immunol.<\/i>, <b>105<\/b>, 651\u2013663 (2000).","DOI":"10.1067\/mai.2000.105712"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Xu L, Yang Y, Wen Y, Jeong JM, Emontzpohl C, Atkins CL, Sun Z, Poulsen KL, Hall DR, Steve Bynon J, Gao B, Lee WM, Rule J, Jacobsen EA, Wang H, Ju C. Hepatic recruitment of eosinophils and their protective function during acute liver injury. <i>J. Hepatol.<\/i>, <b>77<\/b>, 344\u2013352 (2022).","DOI":"10.1016\/j.jhep.2022.02.024"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Moreno-Torres M, Quint\u00e1s G, Castell JV. The potential role of metabolomics in drug-induced liver injury (DILI) assessment. <i>Metabolites<\/i>, <b>12<\/b>, 564 (2022).","DOI":"10.3390\/metabo12060564"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Maris BR, Grama A, Pop TL. Drug-induced liver injury - pharmacological spectrum among children. <i>Int. J. Mol. Sci.<\/i>, <b>26<\/b>, 2006 (2005).","DOI":"10.3390\/ijms26052006"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Bj\u00f6rnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. <i>Aliment. Pharmacol. Ther.<\/i>, <b>25<\/b>, 1411\u20131421 (2007).","DOI":"10.1111\/j.1365-2036.2007.03330.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Wang Y, Yang Y, Wang M, <i>et al<\/i>. Eosinophils attenuate hepatic ischemia-reperfusion injury in mice through ST2-dependent IL-13 production. <i>Sci. Transl. Med.<\/i>, <b>13<\/b>, eabb6576 (2021).","DOI":"10.1126\/scitranslmed.abb6576"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Proctor WR, Chakraborty M, Chea LS, Morrison JC, Berkson JD, Semple K, Bourdi M, Pohl LR. Eosinophils mediate the pathogenesis of halothane-induced liver injury in mice. <i>Hepatology<\/i>, <b>57<\/b>, 2026\u20132036 (2013).","DOI":"10.1002\/hep.26196"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Louis H, Le Moine A, Flamand V, Nagy N, Quertinmont E, Paulart F, Abramowicz D, Le Moine O, Goldman M, Devi\u00e8re J. Critical role of interleukin 5 and eosinophils in concanavalin A-induced hepatitis in mice. <i>Gastroenterology<\/i>, <b>122<\/b>, 2001\u20132010 (2002).","DOI":"10.1053\/gast.2002.33620"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Yu YR, O\u2019Koren EG, Hotten DF, Kan MJ, Kopin D, Nelson ER, Que L, Gunn MD. A protocol for the comprehensive flow cytometric analysis of immune cells in normal and inflamed murine non-lymphoid tissues. <i>PLOS ONE<\/i>, <b>11<\/b>, e0150606 (2016).","DOI":"10.1371\/journal.pone.0150606"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Pham BN, Bemuau J, Durand F, Sauvanet A, Degott C, Prin L, Janin A. Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. <i>J. Hepatol.<\/i>, <b>34<\/b>, 537\u2013547 (2001).","DOI":"10.1016\/S0168-8278(00)00057-X"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Nunes DRDCMA, Breton MC, Monteiro CSJ, Dos Santos JL. Drug induced liver injury: perspective of the adverse drug reaction reports to the Portuguese pharmacovigilance system from 2010 to 2019. <i>Healthcare<\/i> (Basel), <b>9<\/b>, 1630 (2021).","DOI":"10.3390\/healthcare9121630"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ortland I, Mirjalili M, Kullak-Ublick GA, Peymani P. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase<sup>TM<\/sup> from 2010 to 2020. <i>Swiss Med. Wkly.<\/i>, <b>151<\/b>, w20503 (2021).","DOI":"10.4414\/smw.2021.20503"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Akimoto H, Nagashima T, Minagawa K, Hayakawa T, Takahashi Y, Asai S. Signal detection of potential hepatotoxic drugs: case-control study using both a spontaneous reporting system and electronic medical records. <i>Biol. Pharm. Bull.<\/i>, <b>44<\/b>, 1514\u20131523 (2021).","DOI":"10.1248\/bpb.b21-00407"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Medina-C\u00e1liz I, Sanabria-Cabrera J, Villanueva-Paz M, Auk\u0161tikaln\u0117 L, Stephens C, Robles-D\u00edaz M, Pinazo-Bandera JM, Garc\u00eda-Cortes M, Conde I, Soriano G, Bessone F, Hernandez N, Nunes V, Paran\u00e1 R, Lucena MI, Andrade RJ, Niu H, Alvarez-Alvarez I. Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries. <i>Arch. Toxicol.<\/i>, <b>98<\/b>, 303\u2013325 (2024).","DOI":"10.1007\/s00204-023-03630-0"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Watanabe M, Shibuya A, Yokomori H, Koizumi W. The diagnosis of drug-induced liver injury: current diagnostic ability and future challenges of the Digestive Disease Week-Japan 2004 Scale 15 years after its proposal. <i>Intern. Med.<\/i>, <b>60<\/b>, 2557\u20132568 (2021).","DOI":"10.2169\/internalmedicine.6370-20"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. <i>J. R. Stat. Soc. Series B Stat. Methodol.<\/i>, <b>57<\/b>, 289\u2013300 (1995).","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Ib\u00e1\u00f1ez L, P\u00e9rez E, Vidal X, Laporte JR. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. <i>J. Hepatol.<\/i>, <b>37<\/b>, 592\u2013600 (2002).","DOI":"10.1016\/S0168-8278(02)00231-3"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Lucena MI, Andrade RJ, Kaplowitz N, Garc\u00eda-Cortes M, Fern\u00e1ndez MC, Romero-Gomez M, Bruguera M, Hallal H, Robles-Diaz M, Rodriguez-Gonz\u00e1lez JF, Navarro JM, Salmeron J, Martinez-Odriozola P, P\u00e9rez-Alvarez R, Borraz Y, Hidalgo R. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. <i>Hepatology<\/i>, <b>49<\/b>, 2001\u20132009 (2009).","DOI":"10.1002\/hep.22895"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Mao Y, Ma S, Liu C, <i>et al<\/i>. Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update. <i>Hepatol. Int.<\/i>, <b>18<\/b>, 384\u2013419 (2024).","DOI":"10.1007\/s12072-023-10633-7"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, Kleiner DE, Hoofnagle JH. Features of autoimmune hepatitis in patients with drug-induced liver injury. <i>Clin. Gastroenterol. Hepatol.<\/i>, <b>15<\/b>, 103\u2013112.e2 (2017).","DOI":"10.1016\/j.cgh.2016.05.043"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Sharifzadeh S, Mohammadpour AH, Tavanaee A, Elyasi S. Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>77<\/b>, 275\u2013289 (2021).","DOI":"10.1007\/s00228-020-03005-9"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. Too much of a good thing: a retrospective study of \u03b2-lactam concentration-toxicity relationships. <i>J. Antimicrob. Chemother.<\/i>, <b>72<\/b>, 2891\u20132897 (2017).","DOI":"10.1093\/jac\/dkx209"},{"key":"31","unstructured":"31) Wolf A, Schomerus H, Berg P. Severe liver damage as a drug-allergy reaction to cefoperazone. <i>Z. Gastroenterol.<\/i>, <b>23<\/b>, 198\u2013202 (1985)."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Tiwari V, Shandily S, Albert J, Mishra V, Dikkatwar M, Singh R, Sah SK, Chand S. Insights into medication-induced liver injury: Understanding and management strategies. <i>Toxicol. Rep.<\/i>, <b>14<\/b>, 101976 (2025).","DOI":"10.1016\/j.toxrep.2025.101976"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Xu L, Yang Y, Jiang J, Wen Y, Jeong JM, Emontzpohl C, Atkins CL, Kim K, Jacobsen EA, Wang H, Ju C. Eosinophils protect against acetaminophen-induced liver injury through cyclooxygenase-mediated IL-4\/IL-13 production. <i>Hepatology<\/i>, <b>77<\/b>, 456\u2013465 (2023).","DOI":"10.1002\/hep.32609"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ. LiverTox: a website on drug-induced liver injury. <i>Hepatology<\/i>, <b>57<\/b>, 873\u2013874 (2013).","DOI":"10.1002\/hep.26175"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Garg K, Kramer J, Eswaran S. Common gastrointestinal medications implicated in drug-induced liver injury. <i>Clin. Liver Dis. (Hoboken)<\/i>, <b>18<\/b>, 184\u2013188 (2021).","DOI":"10.1002\/cld.1110"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Seife Hassen S, Ata F, Bint IBilal A, Salih Ali M, Petkar M, Awad Elzouki AY, Zahid M. Immune-mediated drug-induced liver injury secondary to omeprazole: a case report. <i>Clin. Case Rep.<\/i>, <b>8<\/b>, 3420\u20133425 (2020).","DOI":"10.1002\/ccr3.3421"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Shin DS, Yang JY, Jeong HN, Mun SJ, Kim H, Son MJ, Bae MA. Hepatotoxicity evaluation method through multiple-factor analysis using human pluripotent stem cell derived hepatic organoids. <i>Sci. Rep.<\/i>, <b>15<\/b>, 10804 (2025).","DOI":"10.1038\/s41598-025-95071-1"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Segovia-Zafra A, Villanueva-Paz M, Serras AS, Matilla-Cabello G, Bodoque-Garc\u00eda A, Di Zeo-S\u00e1nchez DE, Niu H, \u00c1lvarez-\u00c1lvarez I, Sanz-Villanueva L, Godec S, Milisav I, Bagnaninchi P, Andrade RJ, Lucena MI, Fern\u00e1ndez-Checa JC, Cubero FJ, Miranda JP, Nelson LJ. Control compounds for preclinical drug-induced liver injury assessment: consensus-driven systematic review by the ProEuroDILI network. <i>J. Hepatol.<\/i>, <b>81<\/b>, 630\u2013640 (2024).","DOI":"10.1016\/j.jhep.2024.04.026"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) de Abajo FJ, Montero D, Madurga M, Garc\u00eda Rodr\u00edguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. <i>Br. J. Clin. Pharmacol.<\/i>, <b>58<\/b>, 71\u201380 (2004).","DOI":"10.1111\/j.1365-2125.2004.02133.x"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Akimoto H, Nagashima T, Minagawa K, Hayakawa T, Takahashi Y, Asai S. Detection of synergistic interaction on an additive scale between two drugs on abnormal elevation of serum alanine aminotransferase using machine-learning algorithms. <i>Front. Pharmacol.<\/i>, <b>13<\/b>, 910205 (2022).","DOI":"10.3389\/fphar.2022.910205"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Suchin SM, Wolf DC, Lee Y, Ramaswamy G, Sheiner PA, Facciuto M, Marvin MR, Kim-Schluger L, Lebovics E. Potentiation of acetaminophen hepatotoxicity by phenytoin, leading to liver transplantation. <i>Dig. Dis. Sci.<\/i>, <b>50<\/b>, 1836\u20131838 (2005).","DOI":"10.1007\/s10620-005-2947-4"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Jickling G, Heino A, Ahmed SN. Acetaminophen toxicity with concomitant use of carbamazepine. <i>Epileptic Disord.<\/i>, <b>11<\/b>, 329\u2013332 (2009).","DOI":"10.1684\/epd.2009.0274"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Suzuki A, Yuen N, Walsh J, Papay J, Hunt CM, Diehl AM. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. <i>Clin. Gastroenterol. Hepatol.<\/i>, <b>7<\/b>, 882\u2013888 (2009).","DOI":"10.1016\/j.cgh.2009.03.034"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Xie L, Zhang H, Xu L. The role of eosinophils in liver disease. <i>Cell. Mol. Gastroenterol. Hepatol.<\/i>, <b>19<\/b>, 101413 (2025).","DOI":"10.1016\/j.jcmgh.2024.101413"},{"key":"45","unstructured":"45) Mak A, Uetrecht J. Immune mechanisms of idiosyncratic drug-induced liver injury. <i>J. Clin. Transl. Res.<\/i>, <b>3<\/b>, 145\u2013156 (2017)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/1\/49_b25-00620\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:28:19Z","timestamp":1768620499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/1\/49_b25-00620\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00620","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"b25-00620"}}